Zydus Therapeutics, Inc., a wholly owned subsidiary of Zydus Lifesciences Limited (NSE: ZYDUSLIFE; BSE: 532321), has reported new Phase 3 EPICS-III findings showing higher biochemical response rates with investigational saroglitazar than placebo across United States and international populations with primary biliary cholangitis (PBC). Announced on October 12, 2026, for presentation at the American College of Gastroenterology Annual Scientific Meeting, the post hoc geographic analysis found that 60.7% of US patients receiving saroglitazar achieved the prespecified biochemical response criteria at Week 52, compared with none receiving placebo, while corresponding response rates outside the United States were 55.1% and 13.5%.
The exploratory analysis provides additional information about the consistency of treatment effects across the multinational EPICS-III programme, which previously met its primary endpoint in adults with PBC who had an inadequate response to or could not tolerate ursodeoxycholic acid (UDCA). Zydus reported a larger unstratified treatment difference in the US subgroup than in the combined international population, at 60.7 versus 41.6 percentage points. However, the observed difference between geographic subgroups should not be interpreted as evidence that saroglitazar is intrinsically more effective in American patients, particularly because the placebo response differed substantially between regions.
The new findings arrive during an important regulatory period for Zydus Therapeutics. The United States Food and Drug Administration granted Priority Review to the company’s New Drug Application for saroglitazar in May 2026 and assigned a target action date of November 27, 2026. Zydus is preparing for a potential US commercial launch by March 2027, subject to approval, positioning the investigational medicine for possible entry into a rare liver disease market that already includes newer peroxisome proliferator-activated receptor agonists.
The analysis strengthens the characterization of saroglitazar’s biochemical activity, but it does not provide new evidence that treatment prevents liver transplantation, cirrhosis progression or death. Its clinical and commercial relevance will depend on how regulators interpret the complete efficacy and safety package, including the primary Phase 3 findings, the proposed indication and the limitations of surrogate liver biomarkers.
What did the EPICS-III geographic analysis reveal about saroglitazar’s biochemical response?
The geographic analysis examined 148 patients from the randomized Phase 3 portion of EPICS-III, which evaluated saroglitazar magnesium against placebo over 52 weeks. The US population included 42 patients, with 28 assigned to saroglitazar and 14 receiving placebo. The non-US group comprised 106 participants from Argentina, Iceland and Türkiye, including 69 receiving saroglitazar and 37 receiving placebo.
Among US participants, 60.7% of those receiving saroglitazar achieved the composite biochemical response endpoint compared with 0% in the placebo group. Outside the United States, the corresponding proportions were 55.1% and 13.5%. These findings demonstrate that biochemical response rates favoured saroglitazar within both geographic populations.
The reported unstratified treatment difference was 60.7 percentage points in the US subgroup and 41.6 percentage points internationally, giving an apparent geographic difference of 19.1 percentage points. However, the active-treatment response rates differed by only 5.6 percentage points between regions. Much of the larger US treatment difference therefore arose from the absence of biochemical responders among the 14 US placebo recipients, compared with a 13.5% placebo response outside the United States.
This distinction is important because small placebo groups can produce unstable estimates, particularly when no participant achieves the response threshold. The October disclosure did not provide a statistical interaction test establishing that treatment effects genuinely differed by geographic region. The findings are therefore more appropriately interpreted as evidence of favourable biochemical activity across the studied populations than proof of a stronger biological response among US patients.
Why does the post hoc design matter when comparing saroglitazar responses between countries?
EPICS-III was a randomized, double-blind, placebo-controlled trial, providing a stronger foundation for evaluating saroglitazar’s overall efficacy than an uncontrolled clinical investigation. However, the new geographic comparison was performed after the main trial analysis rather than serving as the study’s original primary statistical test. Subgroup findings can generate useful information about treatment consistency, but they require careful interpretation when patient numbers are limited.
The US placebo population contained only 14 participants, making the observed zero-response result particularly sensitive to individual outcomes. A small number of additional responders could have materially changed the estimated treatment difference. The international population was larger, but combining three countries into one comparison group may obscure differences in patient characteristics, disease severity or other clinical factors.
Geographic variation can arise for several reasons beyond differences in a medicine’s pharmacological activity. Baseline alkaline phosphatase concentrations, bilirubin levels, disease duration, prior treatment exposure and patient recruitment practices may influence response patterns. Differences in clinical management and laboratory assessment can also affect comparisons when multiple countries participate in the same trial.
The absence of a reported formal interaction analysis is therefore an important limitation. Demonstrating a statistically significant treatment effect within two subgroups is not the same as demonstrating that those effects differ significantly from each other. For clinicians and regulators, the overall randomized Phase 3 result remains the more important efficacy finding, while the geographic analysis provides supportive information about consistency.
How did saroglitazar perform on alkaline phosphatase normalization and liver enzyme reduction?
The October analysis also examined alkaline phosphatase, or ALP, an enzyme commonly elevated in patients with cholestatic liver disease. ALP is an important biomarker in PBC because sustained elevations are associated with disease progression and poorer long-term outcomes. Reducing ALP is therefore a central objective of second-line treatment development, particularly in patients whose biochemical response to UDCA remains inadequate.
At Week 52, the reported treatment differences for complete ALP normalization were 7.7 percentage points in the US population and 9.6 percentage points outside the United States. Zydus defined normalization using an ALP threshold below 116 units per litre. Unlike the larger geographic difference in composite biochemical response, these normalization treatment differences were relatively similar between regions.
The company also highlighted several participants whose ALP values came close to the normalization threshold without technically meeting it. One US patient receiving saroglitazar had an ALP value of 117 units per litre, while three treated patients in the non-US population recorded values of 118, 119 and 120 units per litre. Although these measurements fell narrowly outside the predefined normalization criterion, they may provide useful context when examining continuous biochemical changes rather than categorizing every patient solely as a responder or nonresponder.
Mean absolute ALP changes also favoured treatment. Among US participants, the mean change from baseline was minus 104 units per litre with saroglitazar, compared with an increase of 62.2 units per litre on placebo, producing a treatment difference of minus 166.2 units per litre. In the non-US group, the corresponding changes were minus 110.9 and minus 6.2 units per litre, giving a treatment difference of minus 104.7 units per litre.
These findings indicate that the investigational medicine reduced ALP in both regional groups, although the larger US comparison again partly reflected the placebo group’s trajectory. Absolute ALP changes can also be influenced by baseline enzyme concentrations, making adjusted and proportional measures useful when evaluating treatment response. The available subgroup summary does not establish that the absolute treatment differences between regions are statistically significant.
What did the original Phase 3 EPICS-III study establish about saroglitazar efficacy?
The geographic findings build on the principal EPICS-III results previously presented at the European Association for the Study of the Liver Congress in May 2026. Following dose selection within the seamless Phase 2b/3 programme, 148 patients were randomized in a 2:1 ratio to receive saroglitazar magnesium 1 milligram or placebo. The active formulation contained approximately 0.97 milligrams of saroglitazar and 0.03 milligrams of magnesium.
The study achieved its primary biochemical response endpoint at Week 52. Overall, 56.7% of saroglitazar-treated patients met the composite response criteria compared with 9.8% receiving placebo, representing a reported treatment difference of approximately 48 percentage points. The result achieved statistical significance at p less than 0.001, with a 95% confidence interval for the treatment difference of 35.3 to 60.8 percentage points.
The endpoint required patients to meet three biochemical criteria. ALP had to fall below 1.67 times the upper limit of normal, decline by at least 15% from baseline, and be accompanied by total bilirubin within the normal range, or direct bilirubin within the normal range for patients with known Gilbert’s syndrome. This combined measure is widely used in PBC drug development because ALP and bilirubin are associated with long-term liver disease outcomes.
Saroglitazar also achieved a favourable overall ALP result, with the company reporting a 33.5% reduction in mean ALP compared with a 6.5% increase among placebo recipients. The approximately 40.1-percentage-point treatment difference strengthens the evidence that the drug produces sustained biochemical activity over the study period. The original topline disclosure also reported success on the key secondary endpoint of ALP normalization.
The controlled Phase 3 evidence is materially stronger than the exploratory geographic comparisons because the primary analysis was designed to test efficacy in the randomized population. Nevertheless, the study primarily establishes effects on biochemical markers rather than direct clinical outcomes. It does not demonstrate that saroglitazar prevents liver transplantation or improves survival, which remain important considerations when evaluating the longer-term significance of treatment.
How does saroglitazar’s PPAR alpha/gamma mechanism compare with existing PBC treatments?
Saroglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist. These receptors regulate biological pathways involved in lipid metabolism, inflammation and other cellular functions relevant to liver disease. By activating these pathways, the medicine is intended to influence bile acid-related liver injury and inflammatory processes associated with PBC.
The investigational therapy enters a market where PPAR agonism is already an established regulatory development approach. Ipsen’s Iqirvo, containing elafibranor, and Gilead Sciences’ Livdelzi, containing seladelpar, received US accelerated approval in 2024 for adults with PBC who respond inadequately to UDCA or cannot tolerate it. Both medicines demonstrated improvements in biochemical response, although their mechanisms, clinical trial designs and safety profiles are not identical.
Zydus may seek to differentiate saroglitazar through its particular receptor activation profile, efficacy findings and tolerability. However, the EPICS-III results do not establish superiority over elafibranor or seladelpar because saroglitazar was compared with placebo rather than either active medicine. Differences in trial populations, baseline ALP measurements, concomitant treatment and statistical methods make direct comparisons of isolated response percentages unreliable.
The commercial environment has also changed following the withdrawal of Ocaliva, containing obeticholic acid, from the US market in 2025. The FDA formally withdrew its approval effective November 24, 2025, after regulatory concerns involving the treatment’s benefit-risk profile and the inability to verify clinical benefit through the required confirmatory evidence. Its withdrawal highlights the importance of demonstrating meaningful long-term outcomes in addition to improvements in biochemical markers.
For Zydus, gaining an approval would establish another therapeutic option, but differentiation will require evidence that clinicians and payers consider relevant. Biochemical efficacy, adverse-event burden, contraindications, interactions, patient eligibility and treatment cost will all influence its eventual positioning.
What safety findings must the FDA examine before approving saroglitazar for PBC?
Zydus reported that saroglitazar was generally well tolerated during EPICS-III, with overall adverse events broadly balanced between treatment and placebo groups. The most commonly reported adverse reactions among saroglitazar recipients included pruritus, headache and urinary tract infection. These findings provide preliminary reassurance within the studied population, although the October geographic analysis did not disclose detailed adverse-event rates by region.
Pruritus deserves particular attention because it is also a frequent and potentially debilitating symptom of PBC itself. Distinguishing treatment-emergent itching from symptoms attributable to the underlying disease can be challenging without detailed baseline measurements and longitudinal assessments. The announcement does not establish that saroglitazar improves pruritus or fatigue, and its biochemical response should not be treated as equivalent to symptom relief.
The FDA’s assessment will also need to examine liver safety, because the proposed treatment is intended for patients with chronic liver disease. Relevant considerations include changes in liver enzymes, bilirubin, treatment discontinuations and adverse events among patients with different levels of hepatic impairment. Longer-term exposure will be important for understanding whether the favourable safety profile reported during the controlled study remains consistent during extended treatment.
Saroglitazar has previously been commercialized in India for specified metabolic indications under the Lipaglyn brand. However, experience with a different dose and indication does not establish the safety or effectiveness of the proposed US PBC regimen. The FDA must evaluate the application according to the evidence supporting the specific product, dose, patient population and intended use under review.
Why is the November 27 FDA decision a major milestone for Zydus Lifesciences?
The FDA accepted saroglitazar’s New Drug Application for review and granted Priority Review in May 2026, assigning a Prescription Drug User Fee Act target action date of November 27. The proposed indication covers treatment in combination with UDCA for adults with an inadequate response to the established first-line therapy, or monotherapy for those unable to tolerate UDCA. The application is supported primarily by the randomized Phase 3 EPICS-III evidence package.
Priority Review means the regulator has assigned an expedited review timeline, but it does not predict approval or establish that a product meets the required benefit-risk standard. The agency may evaluate the adequacy of the trial’s biochemical evidence, the proposed labeling, clinical safety and manufacturing information before reaching its decision. It may also consider what additional clinical evidence would be required under the eventual regulatory pathway.
Zydus has stated that it is preparing to launch saroglitazar in the United States by March 2027 if authorization is granted. This creates a relatively short proposed interval between the regulatory decision and commercial introduction, making product supply, distribution, reimbursement arrangements and specialist engagement important operational considerations. The company has not disclosed a saroglitazar-specific US sales forecast or confirmed pricing strategy.
The parent company’s existing pharmaceutical infrastructure provides some commercial resources, but the PBC market is specialized. Successful introduction would require engagement with hepatologists, gastroenterologists and centres treating rare liver diseases, alongside payer negotiations and patient support arrangements. Regulatory authorization would remove a significant barrier, but it would not automatically guarantee rapid prescribing or insurance coverage.
How are Zydus Lifesciences’ finances and stock performance positioned ahead of the FDA decision?
Zydus Lifesciences approaches the saroglitazar decision as an established pharmaceutical manufacturer with substantial US operations, rather than a biotechnology company dependent on a single investigational medicine. Its business includes generic pharmaceuticals, branded medicines, biologics and research programmes across several therapeutic areas. This diversification provides a broader financial base for commercializing a specialty medicine, although the scale of any eventual saroglitazar contribution remains uncertain.
The company’s first-quarter financial results for the year ending March 2027 showed consolidated revenue growth of approximately 22% year on year. However, consolidated net profit fell to approximately ₹940 crore from ₹1,467 crore in the corresponding prior-year quarter, reflecting pressure from higher operating costs. The divergence between revenue growth and profitability is relevant because successful expansion into innovative specialty products may require additional commercial and development expenditure before generating a sustained earnings contribution.
Zydus Lifesciences shares closed at ₹1,134.40 on the National Stock Exchange on October 12, 2026, gaining ₹16.90, or 1.51%, during the session. The move coincided with the latest saroglitazar disclosure, but there is insufficient evidence to attribute the increase solely to the geographic subgroup analysis. The stock’s performance also reflects the company’s wider pharmaceutical operations, financial expectations and broader Indian equity-market conditions.
The November FDA decision represents a more clearly defined regulatory catalyst than the post hoc presentation itself. Approval could support Zydus’ ambition to expand its innovative medicines business in the United States, while a delay or unfavourable regulatory outcome would alter its planned commercialization timetable. Investors will also need to distinguish the potential value of a new approval from the still-unknown commercial uptake and costs associated with launching the treatment.
What will determine whether saroglitazar becomes a competitive second-line PBC medicine?
The October 2026 analysis adds useful evidence that saroglitazar’s biochemical activity was observed across different geographic populations within the EPICS-III trial. The overall Phase 3 programme has already demonstrated a statistically significant advantage over placebo on its prespecified composite biochemical endpoint, while the latest findings provide additional information about response patterns in US and international patients. The larger numerical US treatment difference is notable, but differences in placebo outcomes and limited subgroup numbers prevent a firm conclusion about geographic superiority.
For clinicians, the most meaningful remaining questions concern the complete safety profile, the drug’s effects on symptoms and the relationship between biochemical improvement and longer-term disease outcomes. Approval based on biochemical measures would provide a regulatory pathway for treatment availability, but the extent to which saroglitazar changes the clinical course of PBC would require further evidence. Its place among established second-line options would also depend on individual patient characteristics and comparative clinical experience.
For Zydus Therapeutics, the next decisive milestone is the FDA’s November 27 target decision date. The company’s planned March 2027 US launch creates a clear commercial objective, although authorization, manufacturing readiness, reimbursement and specialist adoption remain necessary steps. The proposed entry into PBC would expand Zydus Lifesciences’ US specialty portfolio at a time when the market has undergone substantial changes in available therapies.
The latest EPICS-III results therefore strengthen saroglitazar’s existing regulatory evidence rather than establish a new clinical indication or prove superior efficacy in American patients. Its clearest demonstrated benefit remains improvement in ALP and bilirubin-based biochemical response after 52 weeks of treatment. Whether that evidence is sufficient for US authorization, and whether saroglitazar can secure a meaningful position alongside existing PBC medicines, will become clearer with the forthcoming FDA decision and subsequent clinical and commercial developments.
